Yamamoto, Tori N.

Identification of essential genes for cancer immunotherapy

Patel, S. J., Sanjana, N. E., Kishton, R. J., Eidizadeh, A., Vodnala, S. K., Cam, M., Gartner, J. J., Jia, L., Steinberg, S. M., Yamamoto, T. N., et al. (2017) · Nature

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 870

T cell stemness and dysfunction in tumors are triggered by a common mechanism

Vodnala, S. K., Eil, R., Kishton, R. J., Sukumar, M., Yamamoto, T. N., Ha, N.-H., Lee, P.-H., Shin, M., Patel, S. J., Yu, Z., et al. (2019) · Science

T-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

Cited by 552

The B-cell tumor–associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor

Hudecek, M., Schmitt, T. M., Baskar, S., Lupo-Stanghellini, M. T., Nishida, T., Yamamoto, T. N., Bleakley, M., Turtle, C. J., Chang, W.-C., Greisman, H. A., et al. (2010) · Blood

CAR-T cell therapy researchChronic Lymphocytic Leukemia Research

Cited by 266

T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy

Yamamoto, T. N., Lee, P.-H., Vodnala, S. K., Gurusamy, D., Kishton, R. J., Yu, Z., Eidizadeh, A., Eil, R., Fioravanti, J., Gattinoni, L., et al. (2019) · Journal of Clinical Investigation

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 156